Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD)

External Ids:

Disease Ontology 12 DOID:0060175 OMIM® 57 271980 KEGG 36 H00835 MeSH 44 C535803 D000592 ICD10 via Orphanet 33 E72.8

UMLS via Orphanet 71 C0268631 Orphanet 58 ORPHA22 MedGen 41 C0268631 SNOMED-CT via HPO 68 103252009 128613002 162294008 192992007 224958001 228156007 229721007 230413002 230456007 246545002 247578003 248004009 248062006 25786006 258211005 267581004 274521009 277843001 29164008 313307000 37356005 398151007 398152000 405946002 408856003 408857007 432241000124101 43614003 44548000 45352006 48694002 50866000 54200006 61372001 62415009 69322001 7011001 79631006 84757009 85102008 91138005 91175000 95646004 more UMLS 70 C0268631

MedlinePlus Genetics : ⁴³ Succinic semialdehyde dehydrogenase deficiency is a disorder that can cause a variety of neurological problems. People with this condition typically have developmental delay, especially involving speech development; intellectual disability; and decreased muscle tone (hypotonia) soon after birth. About half of those affected experience seizures, difficulty coordinating movements (ataxia), decreased reflexes (hyporeflexia), and behavioral problems. The most common behavioral problems associated with this condition are sleep disturbances, hyperactivity, difficulty maintaining attention, and anxiety. Less frequently, affected individuals may have increased aggression, hallucinations, obsessive-compulsive disorder (OCD), and self-injurious behavior, including biting and head banging. People with this condition can also have problems controlling eye movements. Less common features of succinic semialdehyde dehydrogenase deficiency include uncontrollable movements of the limbs (choreoathetosis), involuntary tensing of the muscles (dystonia), muscle twitches (myoclonus), and a progressive worsening of ataxia.

MalaCards based summary : Succinic Semialdehyde Dehydrogenase Deficiency, also known as 4-hydroxybutyric aciduria, is related to amino acid metabolic disorder and epilepsy, and has symptoms including seizures, ataxia and myoclonic seizures. An important gene associated with Succinic Semialdehyde Dehydrogenase Deficiency is ALDH5A1 (Aldehyde Dehydrogenase 5 Family Member A1), and among its related pathways/superpathways are Alanine, aspartate and glutamate metabolism and Butanoate metabolism. The drugs Neurotransmitter Agents and (3-aminopropyl)(n-butyl)phosphinic acid have been mentioned in the context of this disorder. Affiliated tissues include eye, cortex and globus pallidus, and related phenotypes are intellectual disability and ataxia

Disease Ontology : ¹² A gamma-amino butyric acid metabolism disorder that is characterized by a deficiency of succinic semialdehyde dehydrogenase resulting in elevated levels of gamma-hydroxybutyric acid.

GARD : ²⁰ Succinic semialdehyde dehydrogenase (SSADH) deficiency is a disorder that can cause a variety of neurological and neuromuscular problems. The signs and symptoms can be extremely variable among affected individuals and may include mild to severe intellectual disability ; developmental delay (especially involving speech); hypotonia ; difficulty coordinating movements ( ataxia ); and/or seizures. Some affected individuals may also have decreased reflexes (hyporeflexia); nystagmus ; hyperactivity; and/or behavioral problems. SSADH deficiency is caused by mutations in the ALDH5A1 gene and is inherited in an autosomal recessive manner. Management is generally symptomatic and typically focuses on treating seizures and neurobehavioral issues.

OMIM® : ⁵⁷ Succinic semialdehyde dehydrogenase deficiency (SSADHD) is a rare autosomal recessive neurologic disorder in which an enzyme defect in the GABA degradation pathway causes a consecutive elevation of gamma-hydroxybutyric acid (GHB) and GABA. The clinical features include developmental delay, hypotonia, mental retardation, ataxia, seizures, hyperkinetic behavior, aggression, and sleep disturbances (summary by Reis et al., 2012). (271980) (Updated 20-May-2021)

KEGG : ³⁶ Succinic semialdehyde dehydrogenase (SSADH) deficiency, also known as 4-hydroxybutyric aciduria (4-HBA), is an autosomal recessive inborn error of metabolism. Clinical features include intellectual disability with prominent deficits in expressive language, hypotonia, nonprogressive ataxia, and hyporeflexia. The causative gene is aldehyde dehydrogenase 5 family, member A1 (ALDH5A1) encoding SSADH. SSADH is deficient in affected individuals impairing the formation of succinic acid from succinic semialdehyde and leading to the increased production of 4-HBA.

UniProtKB/Swiss-Prot : ⁷² Succinic semialdehyde dehydrogenase deficiency: A rare inborn error of 4-aminobutyric acid (GABA) metabolism, which leads to accumulation of 4-hydroxybutyric acid in physiologic fluids of patients. The disease is clinically characterized by developmental delay, hypotonia, mental retardation, ataxia, seizures, hyperkinetic behavior, aggression, and sleep disturbances.

Wikipedia : ⁷³ Succinic semialdehyde dehydrogenase deficiency (SSADHD), is a rare autosomal recessive disorder of the... more...

GeneReviews: NBK1195

Clinical features from OMIM®:

271980 (Updated 20-May-2021)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00249-S	9.5	ALDH16A1 ALDH1B1 PRODH SERPINA3
2	Decreased viability	GR00381-A-1	9.5	ABAT PRODH
3	Decreased viability	GR00386-A-1	9.5	ABAT ALDH1B1 ALDH2 ALDH9A1 SLC6A12 SLC6A13
4	Decreased viability	GR00402-S-2	9.5	AKR7A2 ALDH18A1 ALDH9A1

Search NIH Clinical Center for Succinic Semialdehyde Dehydrogenase Deficiency

Search GEO for disease gene expression data for Succinic Semialdehyde Dehydrogenase Deficiency.